Investing in Eledon Pharmaceuticals (ELDN) carries typical clinical-stage biotechnology risks, including high dependency on successful clinical trial outcomes, regulatory approval hurdles from health authorities like the FDA, and potential commercialization setbacks. Because the company is pre-revenue and relies heavily on ongoing research and development expenditures, it faces continuous cash burn, dilution risks from potential future equity offerings, and extreme stock price volatility in response to medical milestone updates.